“Cost-effectiveness Analysis Suggests Price Reductions Needed for Sotorasib to Be a Cost-effective Therapy for KRAS p.G12C-Mutated Advanced NSCLC in the US and China”

https://pubmed.ncbi.nlm.nih.gov/38115313

The abstract reports a cost-effectiveness analysis that suggests sotorasib could potentially be a cost-effective therapy for advanced non-small-cell lung cancer patients with KRAS p.G12C-mutation in the US and China, but only following price reductions.